Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume on Analyst Upgrade

Kura Oncology, Inc. (NASDAQ:KURA) shares saw unusually-strong trading volume on Friday after HC Wainwright raised their price target on the stock from $32.00 to $37.00. HC Wainwright currently has a buy rating on the stock. Approximately 1,545,867 shares changed hands during trading, an increase of 59% from the previous session’s volume of 970,186 shares.The stock last traded at $10.83 and had previously closed at $10.06.

A number of other research firms also recently weighed in on KURA. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities restated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Tuesday. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, November 6th. Finally, UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $29.38.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. nVerses Capital LLC acquired a new stake in Kura Oncology during the 3rd quarter worth $25,000. ProShare Advisors LLC lifted its stake in Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after buying an additional 1,588 shares during the period. Aaron Wealth Advisors LLC boosted its holdings in Kura Oncology by 2.4% during the second quarter. Aaron Wealth Advisors LLC now owns 70,148 shares of the company’s stock worth $1,444,000 after buying an additional 1,673 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Kura Oncology by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after buying an additional 1,976 shares during the period. Finally, Hsbc Holdings PLC increased its stake in shares of Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after acquiring an additional 2,167 shares during the last quarter.

Kura Oncology Stock Up 7.4 %

The firm has a market capitalization of $839.85 million, a price-to-earnings ratio of -4.66 and a beta of 0.86. The business’s 50-day moving average is $18.08 and its two-hundred day moving average is $19.76. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.